You used to be able to, yes.
One of the problems with that, quite frankly, is now you're coming in at a very low price. That's why this patent linkage system and the reform of it is so critical. What's happening now is that you're coming forward with a litigated product, you have approval from the court, Health Canada gives you your science and regulatory approval, and then you launch the product and you're sued for patent infringement. You're selling the product at 18% of the brand name price, and they're suing you for their loss damages, so it's a very complicated thing now for generics. We've actually seen some generics holding back, not launching products to the detriment of the health care system, simply because the risks and rewards are now out of balance.
The best thing that we could do here in Canada at the federal level is simplify that litigation system so there's a final decision when we launch our product.